Literature DB >> 9727066

An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

J J Cornelissen1, R E Ploemacher, B W Wognum, A Borsboom, H C Kluin-Nelemans, A Hagemeijer, B Löwenberg.   

Abstract

IFN-alpha has been shown to prolong survival in chronic myeloid leukemia patients, but its mechanism of action is still not understood. The human cobblestone area-forming cell (CAFC) assay allows for the measurement of the concentration of normal as well as malignant stem cells, while their progeny can be measured in parallel long-term culture (LTC) in flasks. Using CAFC and LTC assays, we have examined direct effects of IFN-alpha (500; 5,000 IU/ml) on the maintenance and outgrowth of CD34-enriched normal and malignant stem cells, obtained from six patients with an established major cytogenetic response to IFN-alpha and from four nonresponding patients. CAFC concentrations were not affected by IFN-alpha. In contrast, IFN-alpha strongly inhibited the clonogenic output in flask LTC. Nucleated cells (NC) produced in LTC were evaluated by fluorescent in situ hybridization (FISH) for the presence of the Philadelphia (Ph) translocation. After 8 wk of LTC, the percentage of Ph+ NCs produced was significantly more inhibited by IFN-alpha in responding patients than in nonresponders. Control LTC without IFN-alpha showed no significant differences of Ph+ NC production between responders and nonresponders. These findings provide the first in vitro model for cytogenetic conversion and suggest that direct antiproliferative effects of IFN-alpha account for the cytogenetic response observed clinically.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727066      PMCID: PMC508963          DOI: 10.1172/JCI2366

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Recessive genetic deregulation abrogates c-myc suppression by interferon and is implicated in oncogenesis.

Authors:  A Kimchi; D Resnitzky; R Ber; G Gat
Journal:  Mol Cell Biol       Date:  1988-07       Impact factor: 4.272

2.  Antigen CD34+ marrow cells engraft lethally irradiated baboons.

Authors:  R J Berenson; R G Andrews; W I Bensinger; D Kalamasz; G Knitter; C D Buckner; I D Bernstein
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

3.  Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.

Authors:  C Selleri; T Sato; L Del Vecchio; L Luciano; A J Barrett; B Rotoli; N S Young; J P Maciejewski
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

4.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.

Authors:  M Talpaz; K B McCredie; G M Mavligit; J U Gutterman
Journal:  Blood       Date:  1983-09       Impact factor: 22.113

5.  Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells.

Authors:  A C Eaves; J D Cashman; L A Gaboury; D K Kalousek; C J Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

7.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K McCredie; J M Trujillo; M J Keating; J U Gutterman
Journal:  N Engl J Med       Date:  1986-04-24       Impact factor: 91.245

8.  Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors.

Authors:  R Agarwal; S Doren; B Hicks; C E Dunbar
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

9.  Close link between reduction of c-myc expression by interferon and, G0/G1 arrest.

Authors:  M Einat; D Resnitzky; A Kimchi
Journal:  Nature       Date:  1985 Feb 14-20       Impact factor: 49.962

10.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage.

Authors:  P J Fialkow; R J Jacobson; T Papayannopoulou
Journal:  Am J Med       Date:  1977-07       Impact factor: 4.965

View more
  2 in total

1.  PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.

Authors:  Shreya Kanodia; Eric Wieder; Sijie Lu; Moshe Talpaz; Gheath Alatrash; Karen Clise-Dwyer; Jeffrey J Molldrem
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

Review 2.  New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.

Authors:  Peter E Westerweel; Peter A W Te Boekhorst; Mark-David Levin; Jan J Cornelissen
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.